An independent clinical research institute conducting kidney trials in Augusta, Georgia for more than 25 years — for the world's leading sponsors, and for the patients of the CSRA.
Our investigators concentrate on the conditions that drive the greatest burden of kidney disease across the Southeast.
Disease-modifying therapies aimed at slowing progression and protecting function across CKD stages.
Agents that protect the diabetic kidney, including SGLT2 and non-steroidal MRA pathways.
Studies at the intersection of heart and kidney disease — including elevated lipoprotein(a) and obesity outcomes.
Investigational therapy for IgA nephropathy, lupus nephritis, and other immune-mediated kidney disease.
Novel approaches to the anemia and mineral-bone complications of advanced kidney disease.
Trials targeting resistant and uncontrolled blood pressure, a principal driver of kidney decline.
Additional experience across dialysis access, hyperparathyroidism, hyperphosphatemia, iron deficiency, hyperlipidemia, proteinuria, polycystic kidney disease, and immunology.
Two decades of continuous kidney-trial experience, inside the region's largest private nephrology practice.
Phase Ib through IV.
From global pharma to emerging biotech and device companies.
Board-certified nephrologists, published in NEJM and leading journals.
Conducting clinical research for more than 25 years.
Southeastern Clinical Research Institute, LLC is an independent clinical research institute incorporated in 2005 — the dedicated trials arm of Nephrology Associates, PC, the largest private-practice nephrology group in the Central Savannah River Area. We exist to bring rigorously studied, next-generation kidney therapies to the people of the CSRA, years before they reach general practice.
Every study is governed by an independent Institutional Review Board, coordinated by an ACRP-certified research team, and overseen by the same board-certified nephrologists who care for our patients every day. Research here is not separate from care. It is an extension of it.
Matthew Diamond, DO, FASN, FACP · Medical Director
Five studies are currently open to enrollment. Eligibility is confirmed by our study team.
Baxdrostat in combination with dapagliflozin, evaluated for renal outcomes and cardiovascular mortality in chronic kidney disease.
Extended TARPEYO® (delayed-release budesonide) treatment in adults with primary IgA nephropathy.
An investigational agent alongside standard of care, evaluated for safety and efficacy in reducing albuminuria.
Retatrutide's effect on cardiovascular and kidney outcomes in adults living with obesity.
Explore the studies enrolling now and find out whether one fits your care — the conversation costs nothing.
Call (706) 922-3005 →Partner with a site that has delivered kidney trials for more than 25 years, from feasibility to closeout.
[email protected] →Southeastern Clinical Research Institute, LLC · 1521 Anthony Road, Augusta, Georgia 30904 · Fax (706) 722-5843